Loading...
About Us 2018-07-10T12:11:37+00:00

rapiplex

Formed in 2009, Biosensia is a science focused, venture backed business established specifically to develop and exploit this novel and proprietary technology, RapiPlex. Biosensia is interested in exploring product commercialisation under license agreement.

The company has core skills in immunology, biochemistry,  microbiology, physics, microfluidics, design engineering, software development and quality/regulatory affairs. Our aim is to make RapiPlex a method of choice for testing multiple analytes in a matter of minutes.

The Biosensia Team

Our management and advisory team have a proven track record
in taking novel products to successful commercialisation

Niamh O’Luanaigh
Niamh O’LuanaighChief Operating Officer
Niamh joined Biosensia in 2011, having previously worked for BBInternational (Alere) for 11 years. Responsible for development of multiple rapid tests and established BBI’s first site outside UK, in USA for development and manufacture of rapid tests.
Smitha Rency
Smitha RencySenior Product Development Scientist
Smitha joined Biosensia in 2013 and has been part of Biosensia’s Technical Team, as a Senior Product Development Scientist and oversees the QMS (IRCA Internal Auditor qualified). She has a strong background in microbiology working in academic and clinical laboratories in India. She is familiar with handling and processing of routine clinical samples, microbiological culture techniques and serological assays.
Dieudonne Sidi
Dieudonne SidiSenior Product Development Scientist
Dieudonne joined Biosensia in 2016 as Product Development Scientist bringing with him substantial experience in lateral flow assay development from Trinity Biotech Ltd. and EKF Diagnostics Ltd. He is a qualified Medical Laboratory Scientist with 5 years’ experience in a clinical facility in Cameroon. He has thorough knowledge in Elisa, Western Blotting, PCR and other Bio-analytical techniques.
Ronan Shanughessy
Ronan ShanughessySenior Product Development Scientist
Ronan joined Biosensia in 2017 when he was awarded a one-year Industry Fellowship by Science Foundation Ireland (SFI). This grant was a collaboration between the company and University College Dublin to develop lateral flow assays to detect microRNAs of diagnostic importance for Tuberculosis. Ronan has a PhD in Immunology and a total of 10 years’ experience researching infectious diseases that has resulted in expertise with a wide range of cellular and molecular techniques.